
Release date: 2026-05-20 14:07:22 Article From: Lucius Laos Recommended: 18
Crizotinib has many drug interactions that may increase side effects or reduce efficacy. Medications to avoid include certain antibiotics (clarithromycin, erythromycin, etc.), antifungals (ketoconazole, itraconazole, etc.), HIV drugs (atazanavir, ritonavir). Meanwhile, antiepileptics (phenytoin, carbamazepine), antituberculosis drugs (rifampin), and herbal products containing St. John's wort may reduce the effectiveness of XALKORI. Conversely, crizotinib can also enhance the side effects of many drugs, such as strong painkillers (fentanyl), antiarrhythmics (quinidine, amiodarone), beta-blockers (atenolol), the antidiabetic metformin, the anticoagulant dabigatran, the lipid-lowering drug pravastatin, the antimalarial mefloquine, the antidepressant bupropion, and the chemotherapy drug irinotecan. Avoid using the above drugs during treatment.
During treatment with crizotinib, avoid drinking grapefruit juice or eating grapefruit, as grapefruit can alter drug levels in the body. The capsules can be taken with or without food. Because this drug may cause photosensitivity (increased sensitivity to sunlight, making sunburn more likely), avoid prolonged sun exposure, wear protective clothing and use sunscreen when outdoors. If you experience visual disturbances, dizziness, or extreme fatigue after taking the medication, be cautious when driving or operating machinery to prevent accidents.
Crizotinib may cause harm to a fetus; therefore, women must not become pregnant and men must not father a child during treatment. Women of childbearing potential must use reliable contraception during treatment and for at least 90 days after the last dose, but should not use oral contraceptives (including combined oral contraceptives and progestin-only pills) because XALKORi reduces their effectiveness. Barrier contraceptive methods are recommended. Pregnant women or those who suspect they are pregnant should consult their doctor before using this medication. Breastfeeding is prohibited during treatment to avoid harming the infant through breast milk.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643